Qiri does not screen a script with one general model. Six Specialist Intelligences reason over it in their own domain, and a pharmacist signs the result. Most scripts need only the first. The rest are there for the ones that do not.
Most scripts are screened by this specialist alone. It works the whole medication profile: interaction chains, renal and hepatic dose review, allergy and contraindication checks, LASA risk, and therapeutic duplication.
The whole medication list at once, not one drug pair at a time.
Dose read against the patient's renal and hepatic function, surfaced for the pharmacist to review.
The patient's allergy record against every active script, before supply.
Look-alike, sound-alike pairs caught at entry, not at the shelf.
Two medicines doing one job, flagged before the patient takes both.
Concentration conversions, dilution factors, and beyond-use dating.
Some scripts turn on the patient's metabolism rather than the drug list. Those come here: cytochrome P450 pathways, PK/PD behaviour, pharmacogenomic results, and therapeutic drug monitoring.
Inhibitors, inducers and substrates across the P450 enzyme families.
Dosing intervals and response curves, not just a number on a label.
Genetic results read as metaboliser phenotypes: poor, intermediate and ultra-rapid.
Serum levels, sample timing, and the dose change that follows.
Current pharmacological literature, cited back to the paper.
High-risk drug-gene pairs flagged against published pharmacogenomic guidelines.
Chemotherapy leaves the least room for error of anything a pharmacy dispenses. This specialist verifies the regimen against protocol, tracks cumulative dose against toxicity ceilings, and flags where a patient sits outside the trial population the guideline was built on.
Regimens against recognised oncology protocol libraries: cycle timing, drug combinations, pre-medications.
Where this patient sits outside the trial population the dosing guideline was built on.
Tumour type, stage, body surface area, and organ function.
Lifetime dose against known ceilings: anthracycline cardiotoxicity, platinum nephrotoxicity.
Anti-emetic, growth factor and prophylactic cover matched to the cycle.
Cycle intervals, rest periods, and safe sequencing across multi-agent regimens.
Pharmacy answers to a medicines regulator, a subsidy scheme, and controlled-substance schedules that vary by jurisdiction. This specialist checks a supply against all of them before it happens.
Scheduling and registration status, current at the moment of supply.
The approval pathways and prescriber notifications your jurisdiction requires for unapproved and special-access medicines.
Eligibility criteria, restriction codes, and authority conditions for subsidised supply.
Controlled-substance schedules, including the record-keeping the most tightly controlled classes require.
Scheduling and subsidy-listing changes, and what each one means for your bench.
An inspection-ready record of every compliance check and decision point.
Every dispense is a decision someone could later ask you to justify. This specialist tests each one against duty of care, professional and regulatory obligations, and the documentation standard a review would apply.
Each decision against the standard of care a review would apply.
Where the risk sits across dispensing, counselling and clinical intervention.
Pharmacy law cases and regulatory decisions relevant to the scenario in front of you.
Notes written to the evidentiary standard a professional review would apply.
The professional conduct and ethics requirements your registration board sets.
Where a decision carries elevated risk, and who it should go to next.
A correct dispense the patient does not understand is not a finished job. This specialist sets counselling to the patient's literacy and language, and points to the support services they are entitled to.
Instructions and side-effect warnings pitched at the patient's reading level.
Counselling and patient materials in the patient's own language.
The social determinants that decide whether the medicine actually gets taken.
Patients drifting off their medicine, early enough to do something about it.
Subsidy safety-net thresholds, and the public health, mental-health, aged-care and disability support pathways patients are entitled to.
Cultural safety for First Nations and culturally and linguistically diverse communities.
No extra screen, and no separate compliance step at the end of the month.